Morabito F, Del Poeta G, Mauro FR, Reda G, et al. TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases. Am J Hematol 2021 May 14. doi: 10.1002/ajh.26235.
PMID: 33989438